Compare Abeona Therapeutics Inc (ABEO) vs ServiceNow Inc (NOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs ServiceNow Inc — how do they compare? Abeona Therapeutics Inc trades at $6.79 (market cap $373.32M), while ServiceNow Inc trades at $107.16 (market cap $114.20B). The key difference: ServiceNow Inc is far larger — about 305.9× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, ServiceNow Inc nearer its low. Which is the better fit depends on your goals.
| ABEO | NOW | |
|---|---|---|
Market Cap | $373.32M | $114.20B |
Sector | Health | Technology |
52-Week High | $7.23 | $204.60 |
52-Week Low | $4.17 | $83.00 |
Enterprise Value | $228.22M | $111.45B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
ServiceNow (NOW) trades at $107.93, up 1.51% today, with a bullish technical outlook supported by positive moving averages. The company reported strong revenue growth to $13.28 billion in 2025 and has beaten earnings estimates in three of the last four quarters. Recent news highlights AI-driven growth potential and conference presentations, while analyst consensus remains strongly bullish with an 85.51% buy rating.
The outlook for NOW is positive due to robust fundamentals and AI adoption, but high valuation multiples (P/E 64.24) pose a risk if growth slows. Upside to the $136.43 price target offers potential, yet investors face volatility from competitive pressures and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
